Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor By Ogkologos - October 12, 2026 292 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the evERA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT... March 13, 2025 Lo que debe saber sobre el cáncer de pulmón October 16, 2020 Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 Latest episode of our podcast for researchers May 23, 2022 Load more HOT NEWS Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait Nurse Who Battled Cancer While In School Surprises Her Dad With... 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... Study Improves the Quality of Biopsy Specimens for Cancer Research
